Autoimmune gastritis: assessment of OLGA and OLGIM staging systems

##plugins.themes.academic_pro.article.sidebar##

Published Dec 15, 2017
Download
pdf
Vol. 95 No. 4 (2017): Issue Apr 2017

##plugins.themes.academic_pro.article.main##

Sana Ben Slama
Dorra Ben Ghachem
Amen Dhaoui
Sarra Ben Rejeb
Mohamed Taieb Jomni
Mohamed Hédi Dougui
Khadija Bellil

Abstract

Background: Autoimmune gastritis present a risk of cancer related to atrophy and intestinal metaplasia. Two recent classifications OLGA (Operative Link on Gastritis Assessment) and OLGIM (Operative Link on Gastritic Intestinal Metaplasia assessment) have been proposed to reveal the high progressive risk forms (stages III and IV).
Aim: To evaluate the OLGA and OLGIM staging systems in chronic autoimmune gastritis.
Methods: A descriptive single institution study of 30 cases of autoimmune gastritis. was performed over a 4-year period. The revaluation of atrophy and intestinal metaplasia, of gastric antrum and corpus, allowed to identify respectively the stages of OLGA and OLGIM systems.
Results: Our autoimmune gastritis were at high-risk stages in 26,5% of cases  according to two classifications. 95% of low-risk gastritis acoording to OLGA staging presented moderete to severe corpus atrophy. A significant association was present between high-risk gastritis according to OLGA staging and neuroendocrine hyperplasia. Both OLGA and OLGIM systems showed a highly significant positive correlation between them with a mismatch at 2%.
Conclusions: The OLGA and OLGIM staging systems in autoimmune gastritis, allow probably selection of high risk forms of chronic gastritis requiring convenable care.

Keywords:

chronic gastritis - atrophic gastritis - intestinal metaplasia - staging.

##plugins.themes.academic_pro.article.details##

References

  1. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007;133:659‑72.
  2. Lahner E, Caruana P, D'Ambra G et al. First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: when should it be done? Gastrointest Endosc 2001;53:443‑8.
  3. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
  4. Rugge M, Pennelli G, Pilozzi E et al. Gastritis: the histology report. Dig Liver Dis 2011;43(4 Suppl):373‑84.
  5. Rugge M, Correa P, Di Mario F et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008;40:650‑8.
  6. Capelle LG, de Vries AC, Haringsma J et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71:1150‑8.
  7. Wun Chan JC, Yu Liu HS, Sang Kho BC et al. Pernicious anemia in Chinese: a study of 181 patients in a Hong Kong hospital. Medicine (Baltimore) 2006;85:129‑38.
  8. Chlumská A, Boudová L, Benes Z, Zámecník M. Autoimmune gastritis. A clinicopathologic study of 25 cases. Ceskoslovenská Patol 2005;41:137‑42.
  9. Annibale B, Marignani M, Azzoni C et al. Atrophic body gastritis: distinct features associated with Helicobacter pylori infection. Helicobacter 1997;2:57‑64.
  10. Torbenson M, Abraham SC, Boitnott J, Yardley JH, Wu T-T. Autoimmune gastritis: distinct histological and immunohistochemical findings before complete loss of oxyntic glands. Mod Pathol 2002;15:102‑9.
  11. Rugge M, Fassan M, Pizzi M et al. Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther 2012;35:1460‑6.
  12. Stolte M, Baumann K, Bethke B, Ritter M, Lauer E, Eidt H. Active autoimmune gastritis without total atrophy of the glands. Z Für Gastroenterol 1992;30:729‑35.
  13. Guarner J, Herrera-Goepfert R, Mohar A et al. Interobserver variability in application of the revised Sydney classification for gastritis. Hum Pathol 1999;30:1431‑4.
  14. Laszlo I, Cseko K, Czimmer J, Mozsik G. Diagnosis of Gastritis - Review from Early Pathological Evaluation to Present Day Management. In: Mozsik G, éditeur. Current Topics in Gastritis - 2012 [Internet]. InTech; 2013 [cited 3 juin 2016]. Available from: http://www.intechopen.com/books/current-topics-in-gastritis-2012/diagnosis-of-gastritis-review-from-early-pathological-evaluation-to-present-day-management
  15. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000;95:1431‑8.
  16. Rugge M, Fassan M, Farinati F, Genta RM. The war of the worlds: metaplastic versus nonmetaplastic atrophic gastritis. Gastrointest Endosc 2011;73:411‑2; author reply 412‑3.
  17. Rugge M, Fassan M, Pizzi M et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol 2011;17:4596‑601.
  18. Weis VG, Goldenring JR. Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer 2009;12:189‑97.
  19. Nam KT, Lee H-J, Sousa JF et al. Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology 2010;139:2028‑37.e9.
  20. Genta RM, Rugge M. Assessing risks for gastric cancer: new tools for pathologists. World J Gastroenterol 2006;12:5622‑7.
  21. Vannella L, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther 2013;37:375‑82.
  22. Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis--pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013;10:529‑41.
  23. Jevremovic D, Torbenson M, Murray JA, Burgart LJ, Abraham SC. Atrophic autoimmune pangastritis: A distinctive form of antral and fundic gastritis associated with systemic autoimmune disease. Am J Surg Pathol 2006;30:1412‑9.
  24. Bergman MP, Vandenbroucke-Grauls CMJE, Appelmelk BJ et al. The story so far: Helicobacter pylori and gastric autoimmunity. Int Rev Immunol 2005;24:63‑91.
  25. Sjöblom SM, Sipponen P, Järvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut 1993;34:28‑32.
  26. Armbrecht U, Stockbrügger RW, Rode J, Menon GG, Cotton PB. Development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow up study of 80 patients. Gut 1990;31:1105‑9.
  27. Lehtola J, Karttunen T, Krekelä I, Niemelä S, Räsänen O. Gastric carcinoids with minimal or no macroscopic lesion in patients with pernicious anemia. Hepatogastroenterology 1985;32:72‑6.
  28. Borch K, Renvall H, Kullman E, Wilander E. Gastric carcinoid associated with the syndrome of hypergastrinemic atrophic gastritis. A prospective analysis of 11 cases. Am J Surg Pathol 1987;11:435‑44.
  29. Vannella L, Sbrozzi-Vanni A, Lahner E et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther 2011;33:1361‑9.
  30. Dinis-Ribeiro M, Areia M, de Vries AC et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74‑94.